Disease with lower urinary tract symptom
Conditions
Interventions
5mg of Tadarafil is administered to the patients once a day for 12 weeks
Sponsors
Fujita Health University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Patients with nocturia(OABSS Total Score 3 or more and Q2 2 or more ) 2.Patients who are considered eligible for the study by the attending physician 3.Patients who can understand the contents of the questionnaire without the help of others, and who can answer on their own 4.Patients who voluntarily provide written consent to participate in the study
Exclusion criteria
Exclusion criteria: 1.Patients with a history of hypersensitivity to components of this drug 2.Patients with a history of serious cardiovascular (It have been reported heart rate increases, and there is a risk that symptoms worse. 3.Patients with severe hypertension 4.Patients with severe liver dysfunction (Child-Pugh score 10 or more) [There is a possibility that the blood concentration is excessively increased.] 5.Patients treated with flecainide acetate or propafenone hydrochloride in administration 6.Patients with chronic bacterial prostatitis or activity of urinary tract infection 7.Patients who carried the radiation therapy to the pelvis 8.Patients who suspected of having prostate cancer by PSA or rectal examination 9.Patients with urethral stricture 10.Patients who are considered ineligible for the study by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improving of urinary symptom score and sleep quality after 12 weeks medication | — |
Secondary
| Measure | Time frame |
|---|---|
| IPSS, QOL, OABSS, athene sleeing score, diary of urination | — |
Countries
Japan
Contacts
Public ContactHitomi Sasaki
Fujita Health University Medicine/Department of Urology
Outcome results
None listed